Table I.
Baseline characteristics of registered patients.
| Variants | Statins (+) (n=10) | % | Statins (−) (n=57) | % |
|---|---|---|---|---|
| Age, years [median (range)] | 70 (53–78) | 67 (36–87) | ||
| Sex | ||||
| Male | 8 | 80.0 | 38 | 66.7 |
| Female | 2 | 20.0 | 19 | 33.3 |
| PS | ||||
| 0/1 | 9 | 90.0 | 50 | 86.7 |
| 2 | 1 | 10.0 | 7 | 13.3 |
| Histological subtypes | ||||
| Adenocarcinoma | 7 | 70.0 | 34 | 59.6 |
| SQC | 2 | 20.0 | 15 | 26.3 |
| NSCLC | 0 | 0 | 4 | 7.0 |
| ADSQC | 0 | 0 | 2 | 3.6 |
| LCNEC | 1 | 10.0 | 1 | 1.8 |
| Large cell carcinoma | 0 | 0 | 1 | 1.8 |
| EGFR mutation | ||||
| Wild-type | 10 | 100.0 | 34 | 77.2 |
| EGFR exon19 del | 0 | 0 | 7 | 12.2 |
| EGFR exon21 L858R | 0 | 0 | 6 | 10.6 |
| Lines of chemotherapy, median (range) | 2 (2–4) | 2 (1–5) | ||
| Smoking Status | ||||
| Current or former | 8 | 100 | 47 | 82.5 |
| Never | 0 | 0 | 10 | 17.5 |
| Use of fibrates | ||||
| Yes | 0 | 0 | 4 | 7.0 |
| No | 10 | 100 | 53 | 93.0 |
| Use of DPP-4 inhibitors | ||||
| Yes | 3 | 30.0 | 2 | 3.5 |
| No | 7 | 70.0 | 55 | 96.5 |
| Use of metformin | ||||
| Yes | 1 | 10.0 | 1 | 1.8 |
| No | 9 | 90.0 | 56 | 98.2 |
PS, performance status; SQC, squamous cell carcinoma; NSCLC, non-small cell lung cancer; ADSQC, adenosquamous cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; EGFR, epidermal growth factor receptor; DPP-4, dipeptidyl-peptidase-4.